AstraZeneca, GlaxoSmithKline and other drugmakers have 89 antibody-drug conjugates for cancer in their pipelines. The therapies are designed to release cytotoxins directly into tumors and are up to 10,000 times as potent as standard chemotherapy but do minimal damage to healthy tissue.
Drugmakers working on powerful, targeted cancer treatments
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.